Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced a landmark deal with an Asian pharmaceutical company, securing a $1.24 billion contract for the production of biopharmaceuticals. This agreement marks the largest single client contract for Samsung Biologics, solidifying its position as a major player in the biopharmaceutical manufacturing landscape.